Caribou Biosciences (CRBU) Competitors $1.87 +0.02 (+1.08%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.84 -0.03 (-1.60%) As of 09/5/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRBU vs. PROK, VIR, KURA, KALV, MNMD, TYRA, ORGO, BCAX, RAPP, and MAZEShould you be buying Caribou Biosciences stock or one of its competitors? The main competitors of Caribou Biosciences include ProKidney (PROK), Vir Biotechnology (VIR), Kura Oncology (KURA), KalVista Pharmaceuticals (KALV), Mind Medicine (MindMed) (MNMD), Tyra Biosciences (TYRA), Organogenesis (ORGO), Bicara Therapeutics (BCAX), Rapport Therapeutics (RAPP), and Maze Therapeutics (MAZE). These companies are all part of the "pharmaceutical products" industry. Caribou Biosciences vs. Its Competitors ProKidney Vir Biotechnology Kura Oncology KalVista Pharmaceuticals Mind Medicine (MindMed) Tyra Biosciences Organogenesis Bicara Therapeutics Rapport Therapeutics Maze Therapeutics Caribou Biosciences (NASDAQ:CRBU) and ProKidney (NASDAQ:PROK) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings. Is CRBU or PROK more profitable? ProKidney has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,800.93%. ProKidney's return on equity of 0.00% beat Caribou Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Caribou Biosciences-1,800.93% -62.35% -49.65% ProKidney N/A N/A -17.11% Do insiders & institutionals hold more shares of CRBU or PROK? 77.5% of Caribou Biosciences shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 8.3% of Caribou Biosciences shares are owned by insiders. Comparatively, 41.5% of ProKidney shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more volatility and risk, CRBU or PROK? Caribou Biosciences has a beta of 2.54, suggesting that its share price is 154% more volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.74, suggesting that its share price is 74% more volatile than the S&P 500. Does the media refer more to CRBU or PROK? In the previous week, ProKidney had 5 more articles in the media than Caribou Biosciences. MarketBeat recorded 5 mentions for ProKidney and 0 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 1.73 beat ProKidney's score of 0.54 indicating that Caribou Biosciences is being referred to more favorably in the media. Company Overall Sentiment Caribou Biosciences Very Positive ProKidney Positive Do analysts rate CRBU or PROK? Caribou Biosciences currently has a consensus target price of $6.67, suggesting a potential upside of 256.51%. ProKidney has a consensus target price of $6.25, suggesting a potential upside of 177.78%. Given Caribou Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Caribou Biosciences is more favorable than ProKidney.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Caribou Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00ProKidney 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has better valuation & earnings, CRBU or PROK? ProKidney has lower revenue, but higher earnings than Caribou Biosciences. ProKidney is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCaribou Biosciences$9.99M17.43-$149.10M-$1.78-1.05ProKidney$80K8,276.63-$61.19M-$0.57-3.95 SummaryProKidney beats Caribou Biosciences on 8 of the 15 factors compared between the two stocks. Get Caribou Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBU and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRBU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRBU vs. The Competition Export to ExcelMetricCaribou BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$174.14M$3.17B$5.83B$9.92BDividend YieldN/A2.26%6.70%4.52%P/E Ratio-1.0521.1076.1526.13Price / Sales17.43432.05553.26185.03Price / CashN/A45.7236.9959.28Price / Book0.679.8711.486.09Net Income-$149.10M-$53.42M$3.29B$266.51M7 Day PerformanceN/A2.93%1.28%0.45%1 Month Performance3.31%11.43%8.56%5.05%1 Year Performance8.72%16.14%61.19%26.03% Caribou Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRBUCaribou Biosciences2.1365 of 5 stars$1.87+1.1%$6.67+256.5%+8.7%$174.14M$9.99M-1.05100Positive NewsPROKProKidney3.1235 of 5 stars$2.36-5.6%$6.25+164.8%-3.4%$694.51M$80K-4.143VIRVir Biotechnology3.4001 of 5 stars$4.94-2.0%$28.44+475.8%-32.1%$686.25M$74.21M-1.24580News CoverageAnalyst ForecastInsider TradeKURAKura Oncology4.1012 of 5 stars$7.90-2.1%$24.10+205.1%-57.4%$685.70M$53.88M-3.50130News CoveragePositive NewsAnalyst ForecastKALVKalVista Pharmaceuticals4.1443 of 5 stars$13.46-0.4%$26.29+95.3%+28.2%$677.57MN/A-3.65100News CoveragePositive NewsUpcoming EarningsMNMDMind Medicine (MindMed)2.5495 of 5 stars$8.88-9.2%$24.71+178.3%+55.1%$675.66MN/A-5.8040News CoveragePositive NewsTYRATyra Biosciences2.7599 of 5 stars$12.67+2.4%$30.83+143.4%-38.6%$675.28MN/A-7.1220News CoveragePositive NewsAnalyst ForecastORGOOrganogenesis4.2577 of 5 stars$5.15+0.6%$7.50+45.6%+102.4%$653.32M$482.04M-36.78950Positive NewsBCAXBicara Therapeutics2.7905 of 5 stars$11.94+0.3%$32.25+170.1%N/A$651.48MN/A-3.7732News CoverageRAPPRapport Therapeutics2.5361 of 5 stars$17.63+4.9%$29.50+67.3%-29.4%$643.46MN/A-7.05N/ANews CoverageMAZEMaze TherapeuticsN/A$14.49+1.5%$25.60+76.7%N/A$635.40M$167.50M0.00121News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies ProKidney Competitors Vir Biotechnology Competitors Kura Oncology Competitors KalVista Pharmaceuticals Competitors Mind Medicine (MindMed) Competitors Tyra Biosciences Competitors Organogenesis Competitors Bicara Therapeutics Competitors Rapport Therapeutics Competitors Maze Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRBU) was last updated on 9/7/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caribou Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Caribou Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
